Alexis Ogdie1,2, Daniel B Shin3, Thorvardur Jon Love4, Joel M Gelfand2,5. 1. Departments of Medicine/Rheumatology. 2. Department of Biostatistics, Epidemiology and Informatics, Perelman School of Medicine. 3. Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA. 4. Department of Medicine, University of Iceland and Landspitali, Reykjavik, Iceland. 5. Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Abstract
OBJECTIVE: Increasing psoriasis severity has been associated with comorbidities including cardiovascular disease. The objective of this study was to examine the association of psoriasis severity with the development of PsA. METHODS: A prospective population-based cohort study was performed within The Health Improvement Network, a UK medical record database. Patients aged 25-60 years with a code for psoriasis were randomly selected between 2008 and 2011. Questionnaires were sent to their general practitioners to confirm the diagnosis of psoriasis and provide the patient's approximate body surface area (BSA). Incidence of PsA was calculated by BSA, and Cox proportional hazard ratios were used to examine the risk of developing PsA by BSA category after adjusting for other covariates. RESULTS: Among 10 474 questionnaires sent, 9987 (95%) were returned, 9069 (91%) had confirmed psoriasis, and BSA was provided for 8881 patients: 52% had mild psoriasis, 36% moderate psoriasis and 12% severe psoriasis. The mean age was 46, and 49% were female. Mean follow-up time was 4.2 years (s.d. 2.1); the incidence of PsA was 5.4 cases per 1000 person-years. After adjusting for age and sex, BSA >10% [hazard ratio (HR) 2.01, 95% CI: 1.29, 3.13], BSA 3-10% (HR 1.44, 95% CI: 1.02, 2.03), obesity (HR 1.64, 95% CI: 1.19, 2.26) and depression (HR 1.68, 95% CI: 1.21, 2.33) were associated with incident PsA. CONCLUSIONS: In this large prospective cohort study, BSA assessed by general practitioners was a strong predictor of developing PsA, and obesity and depression were additive risk factors.
OBJECTIVE: Increasing psoriasis severity has been associated with comorbidities including cardiovascular disease. The objective of this study was to examine the association of psoriasis severity with the development of PsA. METHODS: A prospective population-based cohort study was performed within The Health Improvement Network, a UK medical record database. Patients aged 25-60 years with a code for psoriasis were randomly selected between 2008 and 2011. Questionnaires were sent to their general practitioners to confirm the diagnosis of psoriasis and provide the patient's approximate body surface area (BSA). Incidence of PsA was calculated by BSA, and Cox proportional hazard ratios were used to examine the risk of developing PsA by BSA category after adjusting for other covariates. RESULTS: Among 10 474 questionnaires sent, 9987 (95%) were returned, 9069 (91%) had confirmed psoriasis, and BSA was provided for 8881 patients: 52% had mild psoriasis, 36% moderate psoriasis and 12% severe psoriasis. The mean age was 46, and 49% were female. Mean follow-up time was 4.2 years (s.d. 2.1); the incidence of PsA was 5.4 cases per 1000 person-years. After adjusting for age and sex, BSA >10% [hazard ratio (HR) 2.01, 95% CI: 1.29, 3.13], BSA 3-10% (HR 1.44, 95% CI: 1.02, 2.03), obesity (HR 1.64, 95% CI: 1.19, 2.26) and depression (HR 1.68, 95% CI: 1.21, 2.33) were associated with incident PsA. CONCLUSIONS: In this large prospective cohort study, BSA assessed by general practitioners was a strong predictor of developing PsA, and obesity and depression were additive risk factors.
Authors: Philip J Mease; Dafna D Gladman; Kim A Papp; Majed M Khraishi; Diamant Thaçi; Frank Behrens; Robert Northington; Joanne Fuiman; Eustratios Bananis; Robert Boggs; Daniel Alvarez Journal: J Am Acad Dermatol Date: 2013-08-24 Impact factor: 11.527
Authors: James D Lewis; Rita Schinnar; Warren B Bilker; Xingmei Wang; Brian L Strom Journal: Pharmacoepidemiol Drug Saf Date: 2007-04 Impact factor: 2.890
Authors: Joel M Gelfand; Andrea L Neimann; Daniel B Shin; Xingmei Wang; David J Margolis; Andrea B Troxel Journal: JAMA Date: 2006-10-11 Impact factor: 56.272
Authors: Floranne C Wilson; Murat Icen; Cynthia S Crowson; Marian T McEvoy; Sherine E Gabriel; Hilal Maradit Kremers Journal: Arthritis Rheum Date: 2009-02-15
Authors: Junko Takeshita; Sungat Grewal; Sinéad M Langan; Nehal N Mehta; Alexis Ogdie; Abby S Van Voorhees; Joel M Gelfand Journal: J Am Acad Dermatol Date: 2017-03 Impact factor: 11.527